potential COVID-19 treatments - versus placebo - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.62 [0.43, 0.89]< 10%3 studies (3/-)99.5 %some concernnot evaluable moderatecrucial-
deaths 0.66 [0.51, 0.85]< 10%11 studies (11/-)99.9 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.70 [0.40, 1.21]< 10%1 study (1/-)89.9 %NAnot evaluable crucial-
clinical deterioration 0.43 [0.31, 0.60]< 112%4 studies (4/-)100.0 %lownot evaluable highimportant-
clinical improvement 1.02 [0.61, 1.71]> 149%2 studies (2/-)53.1 %highnot evaluable lowimportant-
clinical improvement (7-day) 0.89 [0.77, 1.03]> 10%2 studies (2/-)6.3 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.13 [0.81, 1.56]> 146%2 studies (2/-)76.1 %highnot evaluable lowimportant-
death or ventilation 0.65 [0.50, 0.86]< 10%2 studies (2/-)99.9 %some concernnot evaluable moderateimportant-
hospital discharge 1.21 [0.98, 1.50]> 117%4 studies (4/-)96.5 %highnot evaluable lowimportant-
hospitalization 0.46 [0.06, 3.45]< 128%2 studies (2/-)77.4 %lownot evaluable highimportant-
mechanical ventilation 0.38 [0.05, 2.67]< 10%3 studies (3/-)83.3 %some concernnot evaluable moderateimportant-
viral clearance 0.94 [0.70, 1.27]> 153%5 studies (5/-)34.4 %lownot evaluable highimportant-
viral clearance (time to event analysis only) 1.00 [0.56, 1.78]> 166%3 studies (3/-)49.9 %lownot evaluable highimportant-
viral clearance by day 14 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %NAnot evaluable important-
viral clearance by day 7 0.92 [0.78, 1.08]> 10%3 studies (3/-)15.4 %lownot evaluable highimportant-
ICU admission 0.75 [0.28, 1.99]< 114%3 studies (3/-)72.0 %some concernnot evaluable moderatenon important-
recovery 0.54 [0.15, 1.94]> 10%1 study (1/-)17.3 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.77 [0.48, 1.21]< 10%4 studies (4/-)87.3 %some concernnot evaluable moderateimportant-
adverse events 2.41 [0.81, 7.14]< 184%5 studies (5/-)5.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.